Freenome (FRNM) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
29 Aug, 2026Executive summary
Blank check company focused on effecting a business combination; no operating revenues to date, only interest income from trust investments.
Net income of $678,555 for Q1 2025, driven by interest income, offset by operating expenses and unrealized losses.
IPO completed June 2024, raising $86.25M (including over-allotment); $2.86M raised from private placement shares.
Financial highlights
Total assets as of March 31, 2025: $90.6M, including $89.3M in the Trust Account.
Cash outside Trust Account: $1.19M; working capital surplus: $1.08M.
Net income for Q1 2025: $678,555, compared to a net loss of $15,397 for the period from inception to March 31, 2024.
Interest income on Trust Account for Q1 2025: $961,912; general and administrative expenses: $255,958.
Accretion for Class A shares to redemption amount: $934,513 in Q1 2025.
Outlook and guidance
Sufficient funds for at least one year of operations from March 31, 2025; no expectation to raise additional funds for current operations.
May require additional financing to complete a business combination or if significant redemptions occur.
Latest events from Freenome
- IPO filing details a well-funded, AI-driven cancer screening innovator with FDA approval and major partnerships.FRNM
Registration filing - SPAC raised $86.25M, reports $1.91M net income, must acquire or liquidate in 24 months.FRNM
Q4 2024 - SPAC holds $91.9M in trust, targets Freenome merger in 2026, but faces going concern risks.FRNM
Q4 2025 - Vote sought to extend business combination deadline by one year, with redemption rights offered.FRNM
Proxy filing - Q1 2026 saw a net loss and rising expenses as the company pursues the Freenome merger.FRNM
Q1 2026 - Q2 2025 net income reached $754,847, with ongoing risks tied to business combination completion.FRNM
Q2 2025 - Vote sought to extend merger deadline by one year; redemption rights and board support highlighted.FRNM
Proxy filing - Q3 net income reached $981,482, with all proceeds held in trust pending a business combination.FRNM
Q3 2024 - IPO completed, $86.25M raised; Q2 net income $102,875; business combination targeted by June 2026.FRNM
Q2 2024